Search results for "HLA-A2"

showing 10 items of 60 documents

The immunodominant CD8 T cell response to the human cytomegalovirus tegument phosphoprotein pp65(495-503) epitope critically depends on CD4 T cell he…

2011

Abstract Immunodominance hierarchies operating in immune responses to viral Ags limit the diversity of the elicited CD8 T cell responses. We evaluated in I-Ab+/A2-HHD-II and HLA-DR1+/A2-DR1 mice the HLA-A*0201–restricted, multispecific CD8 T cell responses to the human CMV tegument phosphoprotein pp65 (pp65) Ag. Vaccination of mice with pp65-encoding DNA elicited high IFN-γ+ CD8 T cell frequencies to the pp65495–503/(e6) epitope and low responses to the pp65320–328/(e3) and pp65522–530/(e8) epitopes. Abrogation of the e6-specific immunity efficiently enhanced e3- and e8-specific T cell responses by a pp65Δ501–503 DNA vaccine. The immunodominant e6-specific (but not the e3- and e8-specific) …

CD4-Positive T-LymphocytesvirusesT cellImmunologyEpitopes T-LymphocyteMice TransgenicImmunodominanceBiologyCD8-Positive T-LymphocytesLymphocyte ActivationTransfectionEpitopeDNA vaccinationViral Matrix ProteinsMiceImmune systemHLA-A2 AntigenmedicineImmunology and AllergyCytotoxic T cellAnimalsHumansAntigen-presenting cellHLA-A AntigensImmunodominant EpitopesVaccinationvirus diseasesPhosphoproteinsVirologyMolecular biologymedicine.anatomical_structureHEK293 CellsPhosphoproteinJournal of immunology (Baltimore, Md. : 1950)
researchProduct

Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity.

2009

The cancer-testis antigen NY-ESO-1 has been targeted as a tumor-associated antigen by immunotherapeutical strategies, such as cancer vaccines. The prerequisite for a T-cell-based therapy is the induction of T cells capable of recognizing the NY-ESO-1-expressing tumor cells. In this study, we generated human T lymphocytes directed against the immunodominant NY-ESO-1(157-165) epitope known to be naturally presented with HLA-A*0201. We succeeded to isolate autorestricted and allorestricted T lymphocytes with low, intermediate or high avidity TCRs against the NY-ESO-1 peptide. The avidity of the established CTL populations correlated with their capacity of lysing HLA-A2-positive, NY-ESO-1-expre…

Cancer ResearchAdoptive cell transferReceptors Antigen T-Cellchemical and pharmacologic phenomenaEnzyme-Linked Immunosorbent AssayStreptamerBiologyEpitopeAntigenAntigens NeoplasmHLA-A2 AntigenCytotoxic T cellHumansAvidityAntigen PresentationHLA-A AntigensT-cell receptorAntibody-Dependent Cell CytotoxicityMembrane ProteinsT lymphocyteCytotoxicity Tests ImmunologicFlow CytometryPeptide FragmentsNeoplasm ProteinsGenes T-Cell ReceptorOncologyImmunologyProtein MultimerizationT-Lymphocytes CytotoxicInternational journal of cancer
researchProduct

Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic t lymphocytes (CTL)

1993

We have pursued our analysis of potential tumor-rejection antigens recognized on human melanoma by autologous cytolytic T lymphocytes (CTL). We reported previously that 3 distinct antigens (A,B,C) were recognized on melanoma cell line SK29-MEL in association with HLA-A2. Selection for melanoma-cell variants resistant to anti-A CTL revealed that antigen A consists of at least 2 determinants (Aa, Ab) which can be lost separately. Genetic linkage between Aa and Ab was suggested by concomitant loss of Aa and Ab in an immunoselected tumor-cell variant. This variant was also resistant to an autologous CTL clone restricted by HLA-B45, indicating that this CTL may also recognize a determinant of an…

Cancer ResearchClone (cell biology)T lymphocyteBiologyCytotoxicity Tests ImmunologicTransfectionVirologyEpitopesCytolysisCTL*OncologyLytic cycleAntigenAntigens NeoplasmHLA-B AntigensHLA-A2 AntigenGene expressionImmunologyTumor Cells CulturedHumansCloning MolecularCytotoxicityMelanomaT-Lymphocytes CytotoxicInternational Journal of Cancer
researchProduct

Overlapping peptides of melanocyte differentiation antigen melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B4…

1998

From the peripheral blood lymphocytes (PBLs) of melanoma patient SK29(AV) we have previously isolated 2 independent cytolytic T lymphocyte (CTL) clones (CTL7/147 and CTL13/211), which lysed autologous tumor cells in association with HLA-B45.1. As demonstrated here, both CTL clones were directed against melanocyte differentiation antigen Melan-A/MART-1, which also was recognized by HLA-A2.1-restricted CTLs from the same patient. By generating and transfecting 3'-deletion mutants of Melan-A/MART-1 cDNA, we localized its peptide-coding regions. The HLA-B45.1-presented peptides were derived from a hydrophobic region of the protein and largely overlapped the peptides recognized by CTLs from the …

Cancer ResearchEpitopes T-LymphocytePeptideHuman leukocyte antigenBiologyEpitopeMART-1 AntigenMelanocyte differentiationAntigenAntigens NeoplasmHLA-A2 AntigenTumor Cells CulturedAnimalsHumansAmino Acid SequenceMelanomachemistry.chemical_classificationBase SequenceSequence Homology Amino AcidDNA NeoplasmT lymphocyteVirologyNeoplasm ProteinsCTL*OncologychemistryHLA-B AntigensCOS CellsClone (B-cell biology)T-Lymphocytes CytotoxicInternational Journal of Cancer
researchProduct

Cellular immune response to human renal-cell carcinomas: Definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-Lymphocyte (CTL) …

1994

Cytotoxic T lymphocyte (CTL) clones directed against autologous renal-cell carcinoma (RCC) cell lines were generated by mixed lymphocyte/tumor-cell culture (MLTC) using peripheral blood lymphocytes (PBL). A CD8+, CD4- CTL clone MZ1257-CTL 5/30 with high cytolytic activity for the autologous tumor cell line MZ1257-RCC was established. No lysis of the autologous EBV-transformed B lymphocytes (EBV-B) or K562 cells was observed. A panel of HLA-A2-matched allogeneic RCC lines was recognized by CTL 5/30. Further specificity analysis showed a cross-reactivity with HLA-A2-matched allogeneic tumor cells of various origins, especially melanoma. CTL 5/30 was also cross-reactive with several HLA-A2-pos…

Cancer ResearchLymphocyteCross ReactionsBiologyKidneyImmune systemAntigenAntigens NeoplasmHLA-A2 AntigenTumor Cells CulturedmedicineHumansCytotoxic T cellCarcinoma Renal CellMelanomaImmunity CellularHistocompatibility Antigens Class IAntibodies MonoclonalT lymphocyteAntigens DifferentiationAutologous tumor cellKidney NeoplasmsCTL*medicine.anatomical_structureOncologyImmunologyLymphocyte Culture Test MixedClone (B-cell biology)T-Lymphocytes CytotoxicInternational Journal of Cancer
researchProduct

Partial tyrosinase-specific self tolerance by HLA-A*0201-restricted cytotoxic T lymphocytes in mice and man

2003

The human tyrosinase (hTyr) (369-377) cytotoxic T lymphocyte (CTL) epitope is presented by malignant melanoma and various nontransformed cells in association with human leukocyte antigen (HLA)-A*0201 (A2.1) and used for vaccination-based immunotherapy of melanoma patients. Its mouse homologue, mTyr (369-377), is naturally processed and bound by A2.1 with equivalent efficacy and thus enabled us to explore the effect of self tolerance on Tyr-specific T cells in different lines of A2.1 transgenic (Tg) mice and man. We found that self Tyr-reactive CTL in Tg mice and, importantly, in man were affected by partial tolerance resulting in only residual T lymphocytes of higher avidity for self Tyr al…

Cancer ResearchT-LymphocytesGenetic VectorsMice Transgenicchemical and pharmacologic phenomenaBiologyEpitopeImmune toleranceEpitopesMiceImmune systemAntigenAntigens CDAntigens NeoplasmHLA-A2 AntigenAnimalsHumansCytotoxic T cellCTLA-4 AntigenIL-2 receptorMelanomaAntigen PresentationHLA-A AntigensMonophenol MonooxygenaseVaccinationReceptors Interleukin-2hemic and immune systemsAntigens DifferentiationMolecular biologyPeptide FragmentsMice Inbred C57BLCTL*Self ToleranceOncologySelf ToleranceImmunologyImmunotherapyT-Lymphocytes CytotoxicInternational Journal of Cancer
researchProduct

Melanoma-Reactive Class I-Restricted Cytotoxic T Cell Clones Are Stimulated by Dendritic Cells Loaded with Synthetic Peptides, but Fail to Respond to…

2003

Abstract Immunization with heat shock proteins (hsp) isolated from cancer cells has been shown to induce a protective antitumor response. The mechanism of hsp-dependent cellular immunity has been attributed to a variety of immunological activities mediated by hsp. Hsp have been shown to bind antigenic peptides, trim the bound peptides by intrinsic enzymatic activity, improve endocytosis of the chaperoned peptides by APCs, and enhance the ability of APCs to stimulate peptide-specific T cells. We have investigated the potential capacity of hsp70 and gp96 to function as a mediator for Ag-specific CTL stimulation in an in vitro model for human melanoma. Repetitive stimulation of PBLs by autolog…

Cellular immunityT cellImmunologyAntigen-Presenting CellsEpitopes T-LymphocyteBiologyLymphocyte ActivationEpitopeInterferon-gammaMART-1 AntigenAntigenAntigens NeoplasmCell Line TumorHLA-A2 AntigenmedicineHumansImmunology and AllergyCytotoxic T cellHSP70 Heat-Shock ProteinsLymphocyte CountAntigen-presenting cellMelanomaHeat-Shock ProteinsCell Line TransformedAntigen PresentationMonophenol MonooxygenaseDendritic CellsMolecular biologyCoculture TechniquesClone CellsNeoplasm ProteinsUp-RegulationCTL*medicine.anatomical_structureCancer cellK562 CellsPeptidesT-Lymphocytes CytotoxicThe Journal of Immunology
researchProduct

A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.

1995

A mutated cyclin-dependent kinase 4 (CDK4) was identified as a tumor-specific antigen recognized by HLA-A2. 1-restricted autologous cytolytic T lymphocytes (CTLs) in a human melanoma. The mutated CDK4 allele was present in autologous cultured melanoma cells and metastasis tissue, but not in the patient's lymphocytes. The mutation, an arginine-to-cysteine exchange at residue 24, was part of the CDK4 peptide recognized by CTLs and prevented binding of the CDK4 inhibitor p16INK4a, but not of p21 or of p27KIP1. The same mutation was found in one additional melanoma among 28 melanomas analyzed. These results suggest that mutation of CDK4 can create a tumor-specific antigen and can disrupt the ce…

Cyclin-Dependent Kinase Inhibitor p21Tumor suppressor geneMutantMolecular Sequence DataCell Cycle ProteinsBiologyProtein Serine-Threonine Kinasesmedicine.disease_causeTransfectionPolymerase Chain ReactionMetastasisCell LineAntigenCyclinsProto-Oncogene ProteinsHLA-A2 AntigenmedicineTumor Cells CulturedAnimalsHumansPoint MutationAmino Acid SequenceCloning MolecularneoplasmsMelanomaCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p15MutationMultidisciplinaryintegumentary systemBase SequenceMelanomaTumor Suppressor ProteinsCyclin-Dependent Kinase 4Cell cyclemedicine.diseaseCyclin-Dependent KinasesCytolysisCancer researchCarrier ProteinsMicrotubule-Associated ProteinsCyclin-Dependent Kinase Inhibitor p27T-Lymphocytes CytotoxicScience (New York, N.Y.)
researchProduct

Detailed characterization of human Mycobacterium tuberculosis specific HLA-E restricted CD8+T cells

2018

HLA-E presented antigens are interesting targets for vaccination given HLA-Es’ essentially monomorphic nature. We have shown previously that Mycobacterium tuberculosis (Mtb) peptides are presented by HLA-E to CD8+effector T cells, but the precise phenotype and functional capacity of these cells remains poorly characterized. We have developed and utilized in this study a new protocol combining HLA-E tetramer with intracellular staining for cytokines, transcription factors and cytotoxic molecules to characterize these cells in depth. We confirm in this study the significantly increased ex vivo frequency of Mtb-peptide/HLA-E-TM+CD8+T cells in the circulation of patients with active tubercu…

Cytotoxicity Immunologic0301 basic medicineTetramersImmunologyHuman leukocyte antigenCD8-Positive T-LymphocytesLymphocyte ActivationCD8+TÂ&nbspArticleImmunophenotypingMycobacterium tuberculosis03 medical and health sciencesTh2Th2 CellsAntigenHLA-A2 AntigenmedicineHumansTuberculosisCytotoxic T cellImmunology and AllergyGranulysinTuberculosis VaccinesCytokineCells CulturedConserved SequenceCell ProliferationAntigens BacterialbiologyLatent tuberculosisHistocompatibility Antigens Class IMycobacterium tuberculosisActive TBcellCD8(+) TcellsFlow Cytometrybiology.organism_classificationmedicine.disease3. Good health030104 developmental biologyPerforinImmunologybiology.proteinCytokinesPeptidesCD8Tetramer
researchProduct

Generation of tumor-reactive CTL against the tumor-associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoiet…

2000

Abstract Ag-specific CD8+ CTL are crucial for effective tumor rejection. Attempts to treat human malignancies by adoptive transfer of tumor-reactive CTL have been limited due to the difficulty of generating and expanding autologous CTL with defined Ag specificity. The current study examined whether human CTL can be generated against the tumor-associated Ag HER2 using autologous dendritic cells (DC) that had been genetically engineered to express HER2. DC progenitors were expanded by culturing CD34+ hemopoietic progenitor cells in the presence of the designer cytokine HyperIL-6. Proliferating precursor cells were infected by a retroviral vector encoding the HER2 Ag and further differentiated…

Cytotoxicity ImmunologicAdoptive cell transferReceptor ErbB-2T cellRecombinant Fusion ProteinsImmunologyAntigen-Presenting CellsImmunoglobulinschemical and pharmacologic phenomenaAntigens CD34BiologyMajor histocompatibility complexLymphocyte ActivationViral vectorCell LineAntigens CDTransduction GeneticMHC class IHLA-A2 AntigenmedicineTumor Cells CulturedImmunology and AllergyHumansProgenitor cellskin and connective tissue diseasesAntigen PresentationMembrane GlycoproteinsInterleukin-6Cell DifferentiationDendritic CellsReceptors InterleukinHematopoietic Stem CellsMolecular biologyReceptors Interleukin-6Peptide FragmentsCell biologyClone CellsCTL*medicine.anatomical_structureRetroviridaebiology.proteinCD8Cell DivisionT-Lymphocytes CytotoxicJournal of immunology (Baltimore, Md. : 1950)
researchProduct